Abstract
e15577 Background: Sunitinib (Su) and Pazopanib (Pa) represent standard first line treatment options for patients with metastatic Renal Cell Carcinoma (mRCC). Hypothyroidism is commonly reported bu...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
